CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
BMS-201038 (AEGR-733) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00405067
NCT00405067Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Active Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of the Combination BMS-201038 (AEGR-733) and Ezetimibe vs. Monotherapy in Subjects With Moderate Hypercholesterolemia

Aegerion Pharmaceuticals, Inc.·interventional·Posted Nov 29, 2006·Updated Mar 4, 2014

In Brief

A Phase 2 clinical trial evaluating BMS-201038 (AEGR-733) and Ezetimibe for Hypercholesterolemia. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The main objectives of this study are to evaluate the efficacy and safety of combination therapy BMS-201038 (AEGR-733) plus ezetimibe vs. each agent given alone on LDL cholesterol and other lipoproteins over 12 weeks of therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 29, 2006
Enrollment StartMay 1, 2006
Primary CompletionJan 1, 2007
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 19.6 years ago

Interventions

BMS-201038 (AEGR-733)drug

Ezetimibedrug